Edward Chung

Deutsche Bank analysts David Steinberg, Edward Chung, and Rosemary Wang maintained a Buy rating for Auxilium Pharmaceuticals (NASDAQ: AUXL), but dropped their price target $10. Auxilium's new drug Xiaflex had a slow launch, falling $2 million short of consensus Q2 estimate of $4 million for Xiaflex...